CDBIO(SH:688739)2022-10-24 16:00Revenue and Profit - Q3 2022 revenue was CNY 478,932,803.95, a decrease of 14.86% year-over-year, while year-to-date revenue reached CNY 1,360,237,730.36, down 21.60% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2022 was CNY 208,089,828.05, a decline of 17.80% year-over-year, with year-to-date net profit at CNY 589,155,273.08, down 28.90%[5] - The net profit after deducting non-recurring gains and losses for Q3 2022 was CNY 193,658,152.11, a decrease of 29.32% year-over-year, and year-to-date it was CNY 527,672,899.23, down 36.56%[5] - Basic earnings per share for Q3 2022 was CNY 0.50, a decrease of 26.47%, while year-to-date basic earnings per share was CNY 1.41, down 36.20%[9] - Total operating revenue for the first three quarters of 2022 was CNY 1,360,237,730.36, a decrease of 21.6% compared to CNY 1,734,997,459.03 in the same period of 2021[30] - Net profit for the third quarter of 2022 was CNY 589,155,273.08, down 29.0% from CNY 828,635,843.67 in the third quarter of 2021[33] - The net profit for the first three quarters of 2022 was approximately CNY 660.63 million, down 21.4% from CNY 840.88 million in the same period of 2021[51] - The total profit for the first three quarters of 2022 was approximately CNY 765.03 million, down 21.1% from CNY 969.90 million in the same period of 2021[51] Cash Flow and Assets - Cash flow from operating activities for the year-to-date period was CNY 310,572,683.78, reflecting a 32.80% increase[9] - As of September 30, 2022, the company's cash and cash equivalents amounted to RMB 4,287,237,727.90, an increase from RMB 2,829,271,603.08 as of December 31, 2021, reflecting a growth of approximately 51.5%[21] - The company's cash inflow from operating activities totaled CNY 1,234,848,778.43, compared to CNY 1,124,479,817.39 in the same period last year[38] - The net cash flow from operating activities for the first three quarters of 2022 was approximately CNY 356.80 million, an increase of 48.8% compared to CNY 239.84 million in the same period of 2021[56] - The net cash flow from investing activities for the first three quarters of 2022 was approximately CNY 1.49 billion, compared to a negative cash flow of CNY 877.94 million in the same period of 2021[56] - Cash and cash equivalents at the end of the period reached CNY 4,250,987,476.02, compared to CNY 347,775,570.81 at the same time last year[41] Research and Development - R&D investment totaled CNY 67,683,330.42 in Q3 2022, accounting for 14.13% of revenue, an increase of 2.01 percentage points year-over-year[9] - Research and development expenses for the first three quarters of 2022 were CNY 162,544,758.79, a slight decrease from CNY 171,514,747.15 in the previous year[30] - The company's research and development expenses for the first three quarters of 2022 were approximately CNY 143.44 million, a decrease of 11.8% compared to CNY 162.63 million in the same period of 2021[51] Assets and Liabilities - Total assets at the end of Q3 2022 were CNY 9,928,282,704.56, an increase of 1.38% from the end of the previous year[9] - The total current assets decreased to RMB 7,639,663,115.05 from RMB 7,797,521,798.66, indicating a decline of about 2.03%[25] - The company's total assets reached RMB 9,928,282,704.56, up from RMB 9,792,731,456.06, representing an increase of approximately 1.38%[25] - The total liabilities decreased to RMB 403,561,883.39 from RMB 440,715,907.97, showing a reduction of about 8.43%[28] - The company's accounts receivable increased to RMB 1,150,408,046.94 from RMB 958,173,371.60, marking a rise of approximately 20.05%[25] - The inventory value rose to RMB 479,723,398.11 from RMB 385,155,199.04, reflecting an increase of about 24.6%[25] - The non-current assets totaled RMB 2,288,619,589.51, up from RMB 1,995,209,657.40, indicating a growth of approximately 14.7%[25] - The company's total equity attributable to shareholders reached CNY 9,524,720,821.17, an increase from CNY 9,352,015,548.09 year-over-year[30] - The total liabilities decreased to CNY 259,439,005.53 from CNY 421,212,228.65 year-over-year[46] Financial Performance and Expenses - Total operating costs decreased to CNY 718,731,679.43 from CNY 752,265,911.84, reflecting a reduction of 4.5%[30] - The company reported a decrease in employee compensation payable from RMB 110,597,075.62 to RMB 72,287,501.59, a decline of about 34.6%[28] - The company reported a decrease in sales expenses to approximately CNY 267.52 million in 2022 from CNY 249.58 million in 2021, reflecting a 7.2% increase[51] - The company’s tax expenses for the first three quarters of 2022 were approximately CNY 104.40 million, a decrease of 19.1% compared to CNY 129.02 million in the same period of 2021[51] - The company’s financial income showed a significant increase, with interest income rising to approximately CNY 36.26 million from CNY 3.77 million in the previous year[51] Company Strategy and Market Conditions - The company reported a decrease in net profit due to the ongoing impact of the COVID-19 pandemic and market competition, but noted that the decline in revenue and profit has narrowed compared to earlier reports in the year[12] - The company has implemented measures to improve sales and manage accounts receivable, contributing to the increase in cash flow from operating activities[12] - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[20]